Sanofi’s 2021 ended on a strong note, with positive takeaways across divisions. While there were some transient challenges in Q4, it doesn’t impact the firm’s performance momentum – also reflecting in a promising 2022 outlook. Overall, the firm remains on track to deliver on its business (transformation) promises and, hence, our positive stock recommendation is reinforced.
